Oculis (NASDAQ:OCS) Price Target Raised to $44.00 at HC Wainwright

Oculis (NASDAQ:OCS) had its price objective hoisted by HC Wainwright from $42.00 to $44.00 in a research report report published on Wednesday,Benzinga reports. They currently have a buy rating on the stock.

OCS has been the topic of a number of other research reports. Bank of America decreased their price target on shares of Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. Wall Street Zen raised Oculis from a “sell” rating to a “hold” rating in a research report on Saturday, November 15th. JPMorgan Chase & Co. initiated coverage on Oculis in a research note on Friday, December 19th. They set an “overweight” rating and a $38.00 target price on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Oculis in a research note on Thursday, January 22nd. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $51.00 price objective on shares of Oculis in a report on Tuesday, November 11th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Oculis currently has an average rating of “Moderate Buy” and a consensus price target of $43.50.

Oculis Trading Up 0.5%

Shares of Oculis stock opened at $27.72 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.47. The business has a fifty day simple moving average of $25.89 and a two-hundred day simple moving average of $21.44. Oculis has a 1 year low of $14.00 and a 1 year high of $30.68. The company has a market capitalization of $1.45 billion, a price-to-earnings ratio of -12.21 and a beta of 0.29.

Oculis (NASDAQ:OCS) last released its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.08). The company had revenue of $0.50 million during the quarter, compared to analyst estimates of $0.14 million. Oculis had a negative net margin of 8,173.41% and a negative return on equity of 67.89%. Research analysts forecast that Oculis will post -2.09 EPS for the current year.

Institutional Trading of Oculis

A number of institutional investors have recently modified their holdings of the stock. Perceptive Advisors LLC acquired a new stake in shares of Oculis during the 4th quarter worth $9,862,000. Millennium Management LLC acquired a new stake in Oculis during the fourth quarter worth about $312,000. NEXTBio Capital Management LP bought a new position in Oculis in the 4th quarter valued at about $2,991,000. Marshall Wace LLP bought a new position in Oculis in the 4th quarter valued at about $914,000. Finally, Alyeska Investment Group L.P. raised its position in shares of Oculis by 152.3% in the 4th quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock valued at $6,617,000 after buying an additional 200,000 shares in the last quarter. 22.30% of the stock is currently owned by institutional investors.

Key Oculis News

Here are the key news stories impacting Oculis this week:

• Positive Sentiment: Analysts raised price targets — HC Wainwright bumped its target to $44 (buy) and Needham raised its target to $40 (buy), giving the stock material upside vs. the current level; these upgrades can attract buying interest. Ticker Report
• Positive Sentiment: Company reported strong strategic progress in the Q4/2025 release: upcoming DIAMOND Phase 3 topline readout for OCS-01 in DME (Q2 2026), Breakthrough Therapy designation for Privosegtor advancing a large neuro-ophthalmology opportunity, and a clear R&D roadmap — these are meaningful clinical catalysts. Press Release
• Positive Sentiment: Balance sheet strength: Oculis reported $268.7M in cash and short-term investments at year-end 2025, which management says funds operations into 2029 — this reduces near-term financing risk and supports value for clinical milestones. Press Release
• Positive Sentiment: Oculis filed its 2025 financials and renewed a $100M at-the-market (ATM) equity program, giving the company optionality to raise capital opportunistically without immediate dilution — investors often view ATMs as a liquidity tool. TipRanks
• Neutral Sentiment: Company published notifications that RSUs vested and were settled for a director; this is routine insider compensation but can incrementally increase share count depending on settlement method. GlobeNewswire
• Negative Sentiment: Q4 earnings: Oculis reported a loss of $0.51/share, missing consensus (-$0.43) despite revenue topping estimates; EPS misses can pressure sentiment, especially for biotech names where near-term commercialization and cash burn matter. Earnings PDF

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.